Advertisement

Recent Aspect of Cyclodextrin-Based Drug Delivery System

  • KANETO UEKAMA
  • FUMITOSHI HIRAYAMA
  • HIDETOSHI ARIMA
Article

Abstract

The pharmaceutically useful cyclodextrins (CyDs) are classified into hydrophilic, hydrophobic, and ionic derivatives. These CyDs can serve as multi-functional drug carriers, through the formation of inclusion complex or the form of CyD/drug conjugate. In addition, the combined use of different CyDs and/or pharmaceutical excipients is capable of alleviating the undesirable properties of drug molecules, improving efficacy and reducing side effects. This contribution outlines the potential use of CyDs in the design and evaluation of CyD-based drug formulation, focusing on their ability to enhance the drug absorption across biological barriers, the ability to control the rate and time profiles of drug release, and the ability to deliver a drug to targeted site.

Keywords

absorption enhancement conjugate controlled drug release cyclodextrin drug carrier inclusion complex pharmaceutical formulation targeting 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Uekama K., Adv. Drug Deliv. Rev. 36 1 (1999)CrossRefGoogle Scholar
  2. 2.
    Uekama K., Chem. Pharm. Bull. 52, 900 (2004)CrossRefGoogle Scholar
  3. 3.
    Irie T., Uekama K., J. Pharm. Sci. 86, 147 (1997)CrossRefGoogle Scholar
  4. 4.
    Uekama K., Hirayama F., Irie T., Chem. Rev. 98, 2045 (1998)CrossRefGoogle Scholar
  5. 5.
    Davis M.E., Brewster M.E., Nat. Rev. 3, 1023 (2004) Google Scholar
  6. 6.
    Szejtli J., Cyclodextrin News 18(1), 1 (2004)Google Scholar
  7. 7.
    Thompson D.O., CRC Crit. Rev. Ther. Drug Carrier Syst. 14, 1 (1997)Google Scholar
  8. 8.
    Irie T., Uekama K., Adv. Drug Deliv. Rev. 36, 101 (1999)CrossRefGoogle Scholar
  9. 9.
    Hirayama F., Uekama K., Adv. Drug Deliv. Rev. 36, 125 (1999) CrossRefGoogle Scholar
  10. 10.
    Uekama K., Minami K., Hirayama F., J. Med. Chem. 40, 2755 (1997)CrossRefGoogle Scholar
  11. 11.
    Arima H., Yunomae K., Hirayama F., Uekama K., J. Pharmacol. Exp. Ther. 297, 547 (2001)Google Scholar
  12. 12.
    Anibarro M., Gessler K., Uson I., Sheldrick M., Harata K., Uekama K., Hirayama F., Saenger W., J. Am. Chem. Soc. 123, 11854 (2001)CrossRefGoogle Scholar
  13. 13.
    Ikeda Y., Motoune S., Marumoto A., Sonoda Y., Hirayama F., Arima H., Uekama K., J. Incl. Phenom. Macrocycl. Chem. 44, 141 (2002)CrossRefGoogle Scholar
  14. 14.
    Wang Z., Hirayama F., Uekama K., J. Pharm. Pharmacol. 46, 505 (1994)Google Scholar
  15. 15.
    Okimoto K., Ohike A., Ibuki R., Ohnishi N., Rajewski R.A., Stella V.J., Irie T., Uekama K., Pharm. Res. 16, 549 (1999)CrossRefGoogle Scholar
  16. 16.
    Kamada M., Hirayama F., Udo K., Yano H., Arima H., Uekama K., J. Control. Rel. 82, 407 (2002) CrossRefGoogle Scholar
  17. 17.
    Yano H., Hirayama F., Arima H., Uekama K., J. Pharm. Sci. 90, 493 (2001)CrossRefGoogle Scholar
  18. 18.
    Yano H., Hirayama F., Kamada M., Arima H., Uekama K., J. Control. Rel. 79, 103 (2002)CrossRefGoogle Scholar
  19. 19.
    Gonzalez H., Hwang S.J., Davis M.E., Bioconjug. Chem. 10, 1068 (1999)CrossRefGoogle Scholar
  20. 20.
    Kihara F., Arima H., Tsutsumi T., Hirayama F., Uekama K., Bioconjug. Chem. 13, 1211 (2002)CrossRefGoogle Scholar
  21. 21.
    Wada K., Arima H., Tsutsumi T., Chihara Y., Hattori K., Hirayama F., Uekama K., J. Control. Rel. 104, 397 (2005)Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • KANETO UEKAMA
    • 1
  • FUMITOSHI HIRAYAMA
    • 1
  • HIDETOSHI ARIMA
    • 1
  1. 1.Graduate School of Pharmaceutical SciencesKumamoto UniversityKumamotoJapan

Personalised recommendations